abstract |
The present invention relates to transglutaminase (4) as a new prostate specific autoantigen, and methods for diagnosis of autoimmune polyendocrine syndrome type 1, autoimmune prostatitis in autoimmune polyendocrine syndrome type 1, and isolated autoimmune prostatitis. The invention further relates to use of transglutaminase (4) and transglutaminase (4) antibodies and antibody conjugates for the treatment prostate cancers. |